Study compares the half-dose and full-dose Pfizer-BioNTech BNT162b2 COVID-19 booster in adults previously vaccinated with ChAdOx1, BBIBP-CorV, or Gam-COVID-Vac. It finds that the half-dose booster has fewer side effects and maintains similar immunogenicity, offering a viable option for booster vaccination strategies.